MY202185A - Carbamoyl phenylalaninol compounds and uses therof - Google Patents
Carbamoyl phenylalaninol compounds and uses therofInfo
- Publication number
- MY202185A MY202185A MYPI2019001915A MYPI2019001915A MY202185A MY 202185 A MY202185 A MY 202185A MY PI2019001915 A MYPI2019001915 A MY PI2019001915A MY PI2019001915 A MYPI2019001915 A MY PI2019001915A MY 202185 A MY202185 A MY 202185A
- Authority
- MY
- Malaysia
- Prior art keywords
- carbamoyl
- uses therof
- compounds
- phenylalaninol compounds
- carbamoyl phenylalaninol
- Prior art date
Links
- NJVZDURTFWBXAM-VIFPVBQESA-N [(2S)-1-hydroxy-3-phenylpropan-2-yl]urea Chemical class C(N)(=O)N[C@@H](CC1=CC=CC=C1)CO NJVZDURTFWBXAM-VIFPVBQESA-N 0.000 title abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
- C07C271/66—Y being a hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
- C07C275/58—Y being a hetero atom
- C07C275/60—Y being an oxygen atom, e.g. allophanic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404917P | 2016-10-06 | 2016-10-06 | |
| PCT/US2017/055598 WO2018067971A1 (en) | 2016-10-06 | 2017-10-06 | Carbamoyl phenylalaninol compounds and uses therof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY202185A true MY202185A (en) | 2024-04-15 |
Family
ID=60183122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2019001915A MY202185A (en) | 2016-10-06 | 2017-10-06 | Carbamoyl phenylalaninol compounds and uses therof |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US10710958B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3523275B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7074750B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102616545B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110049966A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3039045A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2964943T3 (cg-RX-API-DMAC7.html) |
| MY (1) | MY202185A (cg-RX-API-DMAC7.html) |
| PH (1) | PH12019500751A1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201903076QA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018067971A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| MX2020001146A (es) | 2017-07-31 | 2020-08-20 | Jazz Pharmaceuticals Ireland Ltd | Analogos de carbamoil fenilalaninol y usos de los mismos. |
| EP3930702A1 (en) | 2019-03-01 | 2022-01-05 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100197892B1 (ko) | 1994-09-09 | 1999-06-15 | 남창우 | 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법 |
| KR0173862B1 (ko) | 1995-02-11 | 1999-04-01 | 조규향 | O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| US5756817C1 (en) | 1995-02-11 | 2001-04-17 | Sk Corp | O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same |
| KR0173863B1 (ko) | 1995-04-10 | 1999-04-01 | 조규향 | 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| CA2355293C (en) | 1998-12-23 | 2005-08-16 | Orphan Medical, Inc. | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
| US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US6680299B2 (en) | 2001-07-27 | 2004-01-20 | Enanta Pharmaceuticals, Inc. | 4'-substituted leucomycins |
| WO2006050037A1 (en) | 2004-10-28 | 2006-05-11 | Sk Corporation | Adjunctive therapy for depression |
| DK1890684T3 (da) | 2005-06-08 | 2013-10-14 | Sk Biopharmaceuticals Co Ltd | Behandling af søvn/vågenhedsforstyrrelser |
| WO2007001841A1 (en) | 2005-06-22 | 2007-01-04 | Sk Holdings Co., Ltd. | Treatment of sexual dysfunction |
| US8741950B2 (en) * | 2009-06-22 | 2014-06-03 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating or preventing fatigue |
| US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| JP5901528B2 (ja) | 2009-11-06 | 2016-04-13 | エスケー バイオファーマスティカルズ カンパニー リミテッド | 線維筋痛症候群の治療方法 |
| JP5836280B2 (ja) | 2009-11-06 | 2015-12-24 | エスケー バイオファーマスティカルズ カンパニー リミテッド | 注意欠陥／多動性障害（ａｄｈｄ）の治療方法 |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| US9050302B2 (en) | 2013-03-01 | 2015-06-09 | Jazz Pharmaceuticals Ireland Limited | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
| AU2014248849B2 (en) | 2013-03-13 | 2018-08-30 | Jazz Pharmaceuticals Ireland Limited | Treatment of cataplexy |
| CN105848650A (zh) | 2013-07-12 | 2016-08-10 | 爵士制药国际Iii有限公司 | 促进吸烟停止 |
| CN105873576B (zh) * | 2013-07-18 | 2019-07-19 | 爵士制药国际Iii有限公司 | 治疗肥胖 |
| US10888542B2 (en) | 2014-02-28 | 2021-01-12 | Sk Biopharmaceuticals Co., Ltd. | Aminocarbonylcarbamate compounds |
| TWI655179B (zh) | 2014-02-28 | 2019-04-01 | 南韓商愛思開生物製藥股份有限公司 | 胺基羰基胺基甲酸酯化合物 |
-
2017
- 2017-10-06 SG SG11201903076QA patent/SG11201903076QA/en unknown
- 2017-10-06 MY MYPI2019001915A patent/MY202185A/en unknown
- 2017-10-06 JP JP2019518480A patent/JP7074750B2/ja active Active
- 2017-10-06 US US16/338,925 patent/US10710958B2/en active Active
- 2017-10-06 KR KR1020197013113A patent/KR102616545B1/ko active Active
- 2017-10-06 CA CA3039045A patent/CA3039045A1/en not_active Abandoned
- 2017-10-06 EP EP17790906.6A patent/EP3523275B1/en active Active
- 2017-10-06 CN CN201780075629.4A patent/CN110049966A/zh active Pending
- 2017-10-06 WO PCT/US2017/055598 patent/WO2018067971A1/en not_active Ceased
- 2017-10-06 ES ES17790906T patent/ES2964943T3/es active Active
- 2017-10-06 EP EP23199791.7A patent/EP4316592A3/en active Pending
-
2019
- 2019-04-05 PH PH12019500751A patent/PH12019500751A1/en unknown
-
2020
- 2020-06-03 US US16/891,464 patent/US11149000B2/en active Active
-
2021
- 2021-09-09 US US17/470,063 patent/US11780805B2/en active Active
-
2023
- 2023-09-18 US US18/469,032 patent/US20240018098A1/en not_active Abandoned
-
2024
- 2024-11-05 US US18/937,105 patent/US20250059136A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11780805B2 (en) | 2023-10-10 |
| SG11201903076QA (en) | 2019-05-30 |
| KR20190072561A (ko) | 2019-06-25 |
| US11149000B2 (en) | 2021-10-19 |
| US20190218175A1 (en) | 2019-07-18 |
| US20200290955A1 (en) | 2020-09-17 |
| CA3039045A1 (en) | 2018-04-12 |
| EP4316592A3 (en) | 2024-05-01 |
| KR102616545B1 (ko) | 2023-12-26 |
| WO2018067971A1 (en) | 2018-04-12 |
| EP4316592A2 (en) | 2024-02-07 |
| ES2964943T3 (es) | 2024-04-10 |
| US20240018098A1 (en) | 2024-01-18 |
| US20250059136A1 (en) | 2025-02-20 |
| US10710958B2 (en) | 2020-07-14 |
| JP2020503246A (ja) | 2020-01-30 |
| CN110049966A (zh) | 2019-07-23 |
| PH12019500751A1 (en) | 2019-08-05 |
| US20220098145A1 (en) | 2022-03-31 |
| JP7074750B2 (ja) | 2022-05-24 |
| EP3523275B1 (en) | 2023-09-27 |
| EP3523275A1 (en) | 2019-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY202185A (en) | Carbamoyl phenylalaninol compounds and uses therof | |
| SA520411187B1 (ar) | نظائر فينيل ألانينول كربامويل واستخداماتها | |
| PH12019500494A1 (en) | Formulations of (r)-2-amino-3-phenylpropyl carbamate | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| MX2018016046A (es) | Quinazolina y compuestos indol para tratar trastornos medicos. | |
| EP3848370A3 (en) | Tyk2 inhibitors and uses thereof | |
| MX2018006632A (es) | Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4). | |
| MX2020009461A (es) | Anticuerpos anti-proteína que contiene dominio de inmunologlubina rfig elacionado con el receptor de poliovirus (pvrig) y métodos de uso. | |
| EP4327809A3 (en) | Tyk2 inhibitors and uses thereof | |
| EP3735976A3 (en) | Therapeutic use of mitochondria and combined mitochondrial agents | |
| MX2018009773A (es) | Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4). | |
| WO2016134335A3 (en) | Pvrig polypeptides and methods of treatment | |
| MY192927A (en) | Fused bicyclic compounds for the treatment of disease | |
| MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
| EP4351045A3 (en) | Methods and apparatus for setting subband csi-related parameters | |
| MX369623B (es) | Compuestos biciclicos fusionados para el tratamiento de enfermedades. | |
| MX2018006700A (es) | Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4). | |
| MX2018004674A (es) | Moduladores de interacción de sestrina-gator2 y sus usos. | |
| PH12018501279A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
| MX2019000246A (es) | Formas en estado solido del dimesilato de palbociclib. | |
| MX2021006439A (es) | Reguladores del cftr y metodos para su uso. | |
| PH12017501692A1 (en) | Solid forms of menaquinols | |
| EP4480577A3 (en) | Structured elements and methods of use | |
| MX370897B (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades, | |
| GEP201706795B (en) | Hexahydrofuropyrroles as pde1 inhibitors |